Skip to main content

Month: July 2025

Gencor Releases Second Quarter Fiscal 2025 Results

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended March 31, 2025 of $38,204,000 decreased 6.1% from net revenue for the quarter ended March 31, 2024 of $40,676,000. Revenue from contract equipment sales recognized at a point in time decreased slightly in the quarter ended March 31, 2025. As a percent of sales, gross profit margins were 29.7% in the quarter ended March 31, 2025, compared to 30.3% in the quarter ended March 31, 2024 due to a marginally higher material costs. Product engineering and development expenses decreased $212,000 to $681,000 for the quarter ended March 31, 2025, as compared to $893,000 for the quarter ended March 31, 2024, due to reduced headcount. Selling, general and administrative (“SG&A”)...

Continue reading

Gencor Releases First Quarter Fiscal 2025 Results

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended December 31, 2024 of $31,416,000 increased 20.7% over net revenue for the quarter ended December 31, 2023 of $26,018,000. Revenue from contract equipment sales recognized over time increased significantly and was slightly offset by a decrease in parts sales. As a percent of sales, gross profit margins were 27.6% in the quarter ended December 31, 2024, compared to 29.0% in the quarter ended December 31, 2023 due to a smaller contribution of parts sales to total sales in the quarter ended December 31, 2024. Product engineering and development expenses decreased $124,000 to $677,000 for the quarter ended December 31, 2024, as compared to $801,000 for the quarter...

Continue reading

Wabash Announces Second Quarter 2025 Results

Quarterly revenue of $459 million – beating midpoint of outlook range on modestly stronger than expected shipments. Parts & Services generated positive revenue growth sequentially and year-over-year. GAAP operating loss of $5 million or Non-GAAP adjusted operating loss of $0.1 million; Excludes impact of $5 million in expenses associated with the legal verdict. Quarterly GAAP EPS of $(0.23) or Non-GAAP adjusted EPS of $(0.15). Beating Expectations due to slightly higher revenue and cost containment actions throughout the quarter. Total backlog of $1.0 billion ending Q2; Market environment continues to be challenging as economic concerns and uncertainty remain. 2025 revenue outlook reduced to $1.6B, Non-GAAP adjusted EPS outlook reduced to $(1.15), excluding impact in connection with the legal verdict.LAFAYETTE, Ind., July...

Continue reading

Lakeland Financial Reports Record Second Quarter Performance; Net Income Grows by 20% to $27.0 Million, as Net Interest Income Expands by 14%

WARSAW, Ind., July 25, 2025 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported record second quarter net income of $27.0 million for the three months ended June 30, 2025, which represents an increase of $4.4 million, or 20%, compared with net income of $22.5 million for the three months ended June 30, 2024. Diluted earnings per share were $1.04 for the second quarter of 2025 and increased $0.17, or 20%, compared to $0.87 for the second quarter of 2024. On a linked quarter basis, net income increased $6.9 million, or 34%, from $20.1 million. Diluted earnings per share increased $0.26, or 33%, from $0.78 on a linked quarter basis. Pretax pre-provision earnings, which is a non-GAAP measure, were $35.9 million for the three months ended June 30, 2025, an increase...

Continue reading

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors

Pending European Commission (EC) approval, Alhemo® will become available to all adult and paediatric patients 12 years and older living with severe haemophilia A and moderate or severe haemophilia B without inhibitors. This positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is based on results from the explorer8 trial, which showed that Alhemo® reduced spontaneous and traumatic bleeds for patients living with haemophilia A and B without inhibitors compared with no prophylaxis1. If approved by the EC, Alhemo®, with its pen-injector device, has the potential to be an efficacious and easy-to-use option for patients with haemophilia A and B without inhibitors1-3.Bagsværd, Denmark, 25 July 2025 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal...

Continue reading

W&T Offshore Announces Timing of Second Quarter 2025 Earnings Release and Conference Call

HOUSTON, July 25, 2025 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (the “Company”) today announced the timing of its second quarter 2025 earnings release and conference call. The Company said it will issue its second quarter 2025 earnings release on Monday, August 4, 2025, after the close of trading on the NYSE and host a conference call to discuss financial and operational results on Tuesday, August 5, 2025, at 9:00 a.m. Central Time (10:00 a.m. Eastern Time.) Interested parties may participate by dialing (844) 739-3797. International parties may dial (412) 317-5713. Participants should request to be joined to the “W&T Offshore, Inc. Conference Call.” This call will also be webcast and available on W&T Offshore’s website at www.wtoffshore.com under “Investors.” An audio replay will be available on the Company’s...

Continue reading

AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call

MIAMI BEACH, Fla., July 25, 2025 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, today announced it will report second quarter 2025 financial results before market open on Friday, August 1, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13754561 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days. About AirSculpt AirSculpt...

Continue reading

Ambow Launches HybriU Global Learning Network, Connecting U.S. Universities with Students Worldwide

New Phygital Infrastructure Empowers U.S. Universities to Expand Globally Through AI-powered Hybrid Classrooms      CUPERTINO, Calif., July 25, 2025 (GLOBE NEWSWIRE) — Ambow Education Holding Ltd. (NYSE American: AMBO), a U.S.-based innovator of AI-powered phygital (physical + digital) solutions for education, corporate collaboration and live events, today announced the launch of its HybriU Global Learning Network (HGLN), a two-pronged initiative designed to help U.S. universities scale international enrollment and deliver immersive, borderless education. Ambow’s HGLN initiative integrates two core components: the HybriU University Alliance and a network of HybriU Global Learning Centers. Together, these form a comprehensive system that allows U.S. institutions to extend in-person classroom experiences to international students...

Continue reading

Inception Growth Acquisition Limited Announces Adjournment of the Special Meeting to August 8, 2025

New York, July 25, 2025 (GLOBE NEWSWIRE) — Inception Growth Acquisition Limited (the “Company”), a blank check company, today announced that it convened its special meeting (“Special Meeting”) and immediately adjourned the Special Meeting, without conducting any business, to August 8, 2025. The Special Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on May 27, 2025, as supplemented by the supplement to the definitive proxy statement on June 26, 2025 (the “Proxy Statement”), including the proposal to approve the proposed business combination with AgileAlgo Holdings Ltd. As a result of the adjournment, the Special Meeting will now be held at 10:00 AM Hong Kong Time on August 8, 2025, and virtually via teleconference using...

Continue reading

RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call

LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2025 financial results on Monday, August 11, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet’s conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1729070&tp_key=3a3e8702a3. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.